Effectiveness of Platinum-Based Treatment for Triple Negative Metastatic Breast Cancer: a Meta-Analysis

Document Type : Systematic Review and Meta-analysis


1 Medstar Antalya Hospital, Department of Radiation Oncology, Antalya Education and Research Hospital, Antalya,Turkey.

2 Bahcesehir University School of Medicine, Department of Internal Medicine, Medical Oncology, Medicalpark Gaziantep Hospital, Gaziantep, Turkey.

3 Hacettepe University, Department of Radiation Oncology, Ankara, Turkey.

4 Department of Medical Oncology, Antalya Education and Research Hospital, Antalya,Turkey.


Background: Triple-negative breast cancer (TNBC) is a sub-group of breast cancers with a particularly poor
prognosis. The results of studies investigating the role of platinum-based chemotherapy (PBC) in metastatic TNBC
(mTNBC) have been conflicting. In this meta-analysis, our aim was to assess the effectiveness of PBCs for mTNBCs.
Methods: The PubMed, Cochrane Controlled Trials Register Databases, and EBSCOhost databases were accessed.
The English language was used as the search language and only human studies were included. The Newcastle–Ottawa
Quality Assessment Scale and the Jadad scoring system were used to evaluate the quality of the included randomized
controlled studies. Results: Seven studies and 1,571 patients were included in this meta-analysis. The pooled hazard
ratio (HR) for overall survival (OS), evaluated on the basis of six studies, showed the use of PBC regimes to be related
to OS in mTNBCs (HR 0.620; 95% CI 0.513-0.749; p:<0.001). Four studies containing HR and abstract statistics
used for HR calculation were included in the meta-analysis for progression-free survival (PFS). The pooled HR again
indicated a significant relation (HR, 0.628; 95% CI, 0.501-0.786; p:<0.001). Conclusions: In this meta-analysis, we
confirmed that PBC regimes provide OS and PFS advantages compared to non-PBC regimes. The use of PBC regimes
could be a good choice in mTNBC patients for better quality of life and survival.


Main Subjects